Recognizing and Managing Cutaneous Adverse Events from Cancer Therapies

As cancer therapies evolve, dermatologists play an increasingly critical role in managing cutaneous adverse events (CAEs) resulting from these treatments. Understanding the various types of cutaneous reactions and their management strategies is essential for improving patient comfort and adherence to therapy. Understanding Cutaneous Adverse Events CAEs can arise from a multitude of cancer treatments, including chemotherapy, targeted therapies, and immunotherapy. Common CAEs include: Rash: Often presents as maculopapular or exfoliative dermatitis. Dry skin: Frequently reported as a side effect due to epidermal barrier disruption. Hand-foot syndrome: Characterized by erythema and pain on palms and soles. Photosensitivity: Increased sensitivity to UV radiation, leading to sunburn-like reactions. Nail changes: Including onycholysis and pigmentation alterations. Each of these events can vary significantly in their presentation and severity, leading to discomfort and potential discontinuation of therapy. Therefore, dermatologists must be vigilant in recognizing these adverse effects early on. Recognizing Cutaneous Adverse Events Timely identification of CAEs is crucial for effective management. Dermatologists should consider the following when evaluating a patient undergoing cancer treatment: Review the patient's treatment history, focusing on the specific agents used. Assess the timing of skin reactions in relation to the initiation of therapy. Conduct thorough skin examinations to differentiate between drug-induced reactions and underlying disease manifestations. Utilizing standardized grading systems for cutaneous toxicity, such as the Common Terminology Criteria for Adverse Events (CTCAE), can facilitate communication and management strategies. Management Strategies Management of CAEs often requires a multidisciplinary approach. Here are some effective strategies: Topical Treatments: Mild to moderate rashes can be treated with topical corticosteroids or emollients. Fo